Pfizer has today struck a roughly $43 billion deal for Seagen to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in Covid-19 product sales and loss of exclusivity for some top sellers.
The deal, Pfizer's largest since its $67 billion acquisition of Wyeth in 2009, will add four approved cancer therapies with combined sales of nearly $2 billion in 2022.
Pfizer said it would pay $229 in cash per Seagen share, a 32.7% premium to Friday's closing price.
The offer is also a nearly 42% premium to the stock's close on February 24, a day before the Wall Street Journal first reported on a possible deal.
Pfizer has hit the M&A trail with force in its quest to mitigate the impact from an anticipated $17 billion drop in revenue by 2030 due to patent expirations for top drugs and decline in demand for its Covid products.
The drugmaker expects more than $10 billion in "risk-adjusted" sales from Seagen in 2030.
Washington-based Seagen is a pioneer of antibody-drug conjugates (ADCs), which work like "guided missiles" designed for a targeted destructive effect and spares healthy cells.
Pfizer's portfolio of oncology therapies includes 24 approved drugs for cancer, including breast cancer treatment Ibrance.
Pfizer rival Merck & Co and Seagen were in advance deal talks last year but that reportedly collapsed over fears of tough anti-trust scrutiny.
